Cyramza approved for stomach cancer

(HealthDay)—Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach or of the area where the esophagus joins the stomach (the gastroesophageal junction).

Stomach cancer, primarily affecting older people, is expected to be diagnosed in more than 22,000 Americans this year and cause the deaths of about 10,990 people, the FDA said Monday in a news release.

Cyramza works by blocking the blood supply to tumors. It's been approved in advanced cases where the tumor can't be surgically removed, or where the cancer has spread despite the use of other anti-cancer drugs, the agency said.

Cyramza's safety and effectiveness were evaluated in clinical studies involving 355 people. Participants who received the drug lived for an average of 5.2 months compared to 3.8 months among those who took a placebo, the FDA said.

Common side effects included diarrhea and .

Cyramza is marketed by Eli Lilly, based in Indianapolis.

More information: The FDA has more about this approval.

add to favorites email to friend print save as pdf

Related Stories

Nexavar approval expanded for common thyroid cancer

Nov 24, 2013

(HealthDay)—U.S. Food and Drug Administration approval for the anti-cancer drug Nexavar (sorafenib) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid ...

Cometriq approved for rare thyroid cancer

Nov 29, 2012

(HealthDay)—Cometriq (cabozantinib) has been approved by the U.S. Food and Drug Administration to treat modullary thyroid cancer that has spread to other parts of the body, the agency said Thursday.

Zaltrap approved for advanced colorectal cancer

Aug 04, 2012

(HealthDay) -- Zaltrap (ziv-afilbercept) has been approved by the U.S. Food and Drug Administration in combination with a FOLFIRI chemotherapy regimen for adults with advanced metastatic (spreading) colorectal cancer, the ...

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.